Discussion
tumor, tumors, infiltrative disease
GLIOBLASTOMA, TUMOR, TUMORS
Olaparib monotherapy was well tolerated in patients with recurrent or progressive contrast-enhancing PARP is important in the repair of single-strand breaks (Recently, preliminary results of the OLAGLI trial investigating olaparib in 35 patients with recurrent An important concern in the development of novel therapies for CNS tumors is the ability of novel agents to penetrate through areas of intact blood–brain barrier to address infiltrative disease. CNS penetration of olaparib in humans has been shown in a phase I study combining temozolomide with olaparib in patients with relapsed glioblastoma; olaparib, given prior to surgery, was detected in 71 of 71 tumor core specimens from 27 patients (Identifying mutations that further define distinct subgroups within In addition to PARPi, a significant focus of research in There are numerous future study directions in this population. Trials investigating timing of 